News Releases

June 01, 2022
Arrakis Therapeutics to Present at Jefferies Healthcare Conference
March 31, 2022
Arrakis Therapeutics to Participate in Upcoming Investor Conferences
February 08, 2022
Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference
January 11, 2022
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
January 10, 2022
Arrakis Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
December 06, 2021
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
March 23, 2021
Arrakis Therapeutics Announces New Scientific Advisory Board Members
November 19, 2020
Arrakis Therapeutics Appoints Patrizio Renzetti as Vice President of Human Resources
August 31, 2020
Arrakis Therapeutics Publishes Advanced Research Method To Systematically Identify RNA-Targeted Small Molecules
July 15, 2020
Arrakis Therapeutics Appoints Erik Spek, Ph.D., J.D., as Vice President, Legal and Intellectual Property
April 08, 2020
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
February 05, 2020
Arrakis Therapeutics Appoints Jacques Dumas, Ph.D., as Senior Vice President, Drug Discovery
November 21, 2019
Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors
April 18, 2019
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
October 02, 2018
FierceBiotech names Arrakis Therapeutics as one of its “Fierce 15” Biotech Companies of 2018
January 10, 2018
Arrakis Therapeutics Named as an “Endpoints 11” Disruptive Biotech Company of 2017
October 25, 2017
Arrakis Therapeutics Announces Release of SHAPEware™ Bioinformatics Tools as Open-Source Software
May 02, 2017
Arrakis Congratulates Its SAB Chair, Melissa Moore, PhD, on Election to National Academy of Sciences
February 27, 2017
Arrakis Therapeutics Announces $38 Million Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO
© 2022 Arrakis Therapeutics. All rights reserved.
Back to Top